

CME FROM MEDIMMUNE: Analyzing the Impact of Amifostine on Patient Outcomes

By Robert Haddad, MD, Associate Director of Clinical Cancer Research, Head and Neck Oncology Program, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA

Release Date: November 2003

Expiration Date: November 2005

Case Study: A Patient With Head and Neck Cancer Treated With Definitive, Concomitant Chemoradiation and Amifostine

Target Audience

This CME activity will be beneficial for medical and radiation oncologists, as well as for other healthcare personnel involved in treating patients with head and neck cancer.

Learning Objectives

Upon completion of this CME activity, participants should be able to:

- > Discuss options to reduce toxicities associated with radiation and/or chemotherapy.
- > Describe approaches to incorporating amifostine into cancer therapies.
- > Cite studies that analyze the use of amifostine, cytoprotection, and/or certain cancer therapy regimens for the malignancies presented.
- > Describe how the use of amifostine may affect patients, therapies, and/or treatment outcomes.

Accreditation Statement

Medical Education Group LLC is accredited by the Accreditation Council for Continuing Medical Education to sponsor continuing medical education for physicians.

Credit Designation

Medical Education Group LLC designates this educational activity for up to **one-half (0.5) hour in category 1 credit toward the AMA Physician's Recognition Award**. Each physician should claim only those hours of credit that he/she actually spent in the educational activity.

Acknowledgment

Medical Education Group LLC acknowledges an unrestricted educational grant from MedImmune Oncology, Inc. in support of this CME activity.

Registration Information

Visit Oncology Associates' web site at **www.oagpo.com** to access this CME online, or order a printed copy by contacting MedImmune Oncology at **877-633-4411**.



Web Watch: Point and Click for our Top Web Picks

www.patientadvocate.org

Patient Advocate Foundation is a national non-profit organization that serves as an active liaison between the patient and their insurer, employer and/or creditors to resolve insurance, job retention and/or debt crisis matters relative to their diagnosis.

www.asco.org

Visit the publication link on the homepage of ASCO's web site to order the book, **Practical Tips for the Practicing Oncologist**. This latest edition answers the most commonly asked questions about coding, coverage, reimbursement and regulatory issues for medical oncology services. A must-have for every practice!

www.managecinv.com

Nurses, Take the CINV Challenge! After completing the CINV Challenge, you will earn a \$25 education stipend. You have the option to redeem this stipend for a MedSite Rewards certificate, good toward the purchase of educational materials. Users also have the option to donate this stipend to 1 of 3 Oncology non-profit organizations.

ONLINE CE FROM NOVARTIS: Update on Extended Adjuvant Therapy Options in Breast Cancer

Sponsored by an unrestricted educational grant from Novartis Oncology

This online activity is available through June 30, 2006.

Overview

This program looks at extended adjuvant therapy options in breast cancer. We will be focusing on adjuvant therapies used in post-menopausal women with advanced

breast cancer and with disease progression following traditional anti-estrogen therapy.

Target Audience

This program is for oncology nurses interested in learning about the role of aromatase inhibitors in breast cancer management.

Contact Hours: **1.7 Contact Hours**

Registration Information

Visit **www.ons.org** to access this online CE activity. Click on the Nursing Education link at the top of the homepage.